MX2017014162A - Una composicion farmaceutica antiviral de uso topico. - Google Patents

Una composicion farmaceutica antiviral de uso topico.

Info

Publication number
MX2017014162A
MX2017014162A MX2017014162A MX2017014162A MX2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A MX 2017014162 A MX2017014162 A MX 2017014162A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
topical use
antiviral
composition antiviral
quaternary ammonium
Prior art date
Application number
MX2017014162A
Other languages
English (en)
Other versions
MX384814B (es
Inventor
Alberto Argañaras Luis
Original Assignee
Quim Luar S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quim Luar S R L filed Critical Quim Luar S R L
Publication of MX2017014162A publication Critical patent/MX2017014162A/es
Publication of MX384814B publication Critical patent/MX384814B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica antiviral de uso tópico contra aquellos virus con envoltura lipídica, que comprende como principios activos un copolímero catiónico conteniendo grupos aminos terciarios, y un tensioactivo catiónico conteniendo grupos amonios cuaternarios.
MX2017014162A 2015-05-15 2016-05-13 Composición farmacéutica antiviral de uso tópico que comprende copolímero catónico y tensoactivo catónico. MX384814B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico
PCT/ES2016/070365 WO2016185069A1 (es) 2015-05-15 2016-05-13 Una composición farmacéutica antiviral de uso tópico

Publications (2)

Publication Number Publication Date
MX2017014162A true MX2017014162A (es) 2018-06-20
MX384814B MX384814B (es) 2025-03-14

Family

ID=57319498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014162A MX384814B (es) 2015-05-15 2016-05-13 Composición farmacéutica antiviral de uso tópico que comprende copolímero catónico y tensoactivo catónico.

Country Status (11)

Country Link
US (1) US10478452B2 (es)
EP (1) EP3295934B1 (es)
AR (1) AR100459A1 (es)
BR (1) BR112017024399B1 (es)
CL (1) CL2017002796A1 (es)
CO (1) CO2017011297A2 (es)
ES (1) ES2915824T3 (es)
IL (1) IL255635A (es)
MX (1) MX384814B (es)
PE (1) PE20180396A1 (es)
WO (1) WO2016185069A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022060747A (ja) * 2020-10-05 2022-04-15 サンスター株式会社 抗ウイルス用口腔用組成物
EP4324467A4 (en) * 2021-04-16 2025-04-02 Nippon Shokubai Co., Ltd. ANTI-CORONAVIRUS AGENTS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4902720A (en) * 1983-01-10 1990-02-20 Baldone Joseph A Treatment of virus infections with quaternary ammonium compounds
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
TR200200763T2 (tr) * 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
US6855341B2 (en) 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
WO2012131669A1 (en) * 2011-03-29 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Film-forming composition for a ph-dependant sustained release of the active agent

Also Published As

Publication number Publication date
EP3295934B1 (en) 2022-03-02
CL2017002796A1 (es) 2018-07-13
CO2017011297A2 (es) 2018-01-31
WO2016185069A1 (es) 2016-11-24
BR112017024399A2 (pt) 2019-02-05
EP3295934A4 (en) 2019-01-02
IL255635A (en) 2018-01-31
US10478452B2 (en) 2019-11-19
US20180250327A1 (en) 2018-09-06
BR112017024399B1 (pt) 2022-06-07
EP3295934A1 (en) 2018-03-21
PE20180396A1 (es) 2018-02-28
MX384814B (es) 2025-03-14
ES2915824T3 (es) 2022-06-27
AR100459A1 (es) 2016-10-05

Similar Documents

Publication Publication Date Title
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
MX2016016647A (es) Metodo para preparar una composicion estable con perfume.
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
BR112015009189A2 (pt) conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo
BR112015000520A2 (pt) agente de espessamento estável com lipase
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
CO2017007316A2 (es) Formulación farmacéutica
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112016005417A8 (pt) "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos"
MX2017016818A (es) Uso de un copolimero anfolito como estabilizador coloidal.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
CR20150145A (es) Composiciones con matriz de resina fundida en caliente
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
CO2018005491A2 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CO2017011297A2 (es) Una composición farmacéutica antiviral de uso tópico
BR112017022553A2 (pt) métodos e materiais para matar células infectadas por hiv
BR112017018707A2 (pt) composições compreendendo compostos de mentol como agentes suavizantes